Market Cap 110.61M
Revenue (ttm) 0.00
Net Income (ttm) -210.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 498,435
Avg Vol 783,744
Day's Range N/A - N/A
Shares Out 61.45M
Stochastic %K 74%
Beta 1.41
Analysts Sell
Price Target $2.81

Company Profile

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6770
Address:
331 Oyster Point Boulevard, South San Francisco, United States
NolAsrtormZ
NolAsrtormZ Nov. 13 at 12:03 AM
$KRRO.... busted data ??? Data chasers come on down to $GRI bio---- ipf data due soon. Trades at $1.86 An idea of how much iPf data is worth $PLRX lost 900 million market cap $TVRD lost 300 million market cap $ARCT lost 300 million market cap. Safe to say ipf data is worth 300 million market cap. Gri bio is at 4.6million market cap. $0 or $126 w good data
0 · Reply
NolAsrtormZ
NolAsrtormZ Nov. 12 at 5:40 AM
$GRI... i still like to think iPf data is worth 300 million market cap. If you look at $TVRD data drop 300 million market cap If you look at $ARCT dropped 300 million market cap If you look at $PLRX ipf discontinued data dropped 900 million market cap Data $0 or $126
0 · Reply
sandman7473
sandman7473 Nov. 9 at 10:29 PM
$PLRX tutes buy after the collapse. This is either going to moon after data or a liquidation event. Just my thoughts. Gl next week.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 7:19 PM
RBC Capital has adjusted their stance on Pliant Therapeutics ( $PLRX ), setting the rating to Sector Perform with a target price of 3 → 2.
0 · Reply
KMKuk2lg2022
KMKuk2lg2022 Nov. 7 at 3:38 PM
$PLRX management and board a dogsh*t and everything is wrong with biotech! They are burning through cash and no end in sight! After the shitty data on IPF they should have done what Third Harmonic did and go for shutdown...Considering very few phase 2b or phase 3 drug candidates out there to buy or license, they can only go for reverse merger if all the folks like Tang who bought at 3.44$ want PLRX to be above 4$ in value. There shouldn't be any bonus or upping options for them. 9 months of burning cash is not on! So crazy...
1 · Reply
d_risk
d_risk Nov. 7 at 3:53 AM
$PLRX - Pliant Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors PLRX’s latest 10-Q risk factors spotlight deepening net losses, higher funding needs after discontinuing bexotegrast in IPF, unpredictable clinical and regulatory timelines, and heavy reliance on third parties. New risks include failed opportunity evaluations, exclusive forum bylaws, data protection compliance, cybersecurity, Brexit, tax law changes, analyst coverage, and social media missteps. #Biotechnology #Cybersecurity #RegulatoryUncertainty #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/PLRX/10-Q/2025-11-06
0 · Reply
sandman7473
sandman7473 Nov. 7 at 12:32 AM
$PLRX muted as expected. Is point72 and tang waiting for data eoy? Gl.
0 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 6 at 9:07 PM
$PLRX Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-provides-corporate-update-and-reports-17 As of September 30, 2025, the Company had cash, cash equivalents and short-term investments of $243.3 million.
0 · Reply
Vinniesb
Vinniesb Nov. 6 at 5:22 PM
0 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 4 at 8:54 PM
$PLRX i increased my position today. News anyday
0 · Reply
Latest News on PLRX
Pliant Therapeutics Provides Update on BEACON-IPF

Jun 27, 2025, 4:05 PM EDT - 5 months ago

Pliant Therapeutics Provides Update on BEACON-IPF


Pliant Therapeutics: An Activist On Deck

Apr 3, 2025, 12:22 PM EDT - 8 months ago

Pliant Therapeutics: An Activist On Deck


NolAsrtormZ
NolAsrtormZ Nov. 13 at 12:03 AM
$KRRO.... busted data ??? Data chasers come on down to $GRI bio---- ipf data due soon. Trades at $1.86 An idea of how much iPf data is worth $PLRX lost 900 million market cap $TVRD lost 300 million market cap $ARCT lost 300 million market cap. Safe to say ipf data is worth 300 million market cap. Gri bio is at 4.6million market cap. $0 or $126 w good data
0 · Reply
NolAsrtormZ
NolAsrtormZ Nov. 12 at 5:40 AM
$GRI... i still like to think iPf data is worth 300 million market cap. If you look at $TVRD data drop 300 million market cap If you look at $ARCT dropped 300 million market cap If you look at $PLRX ipf discontinued data dropped 900 million market cap Data $0 or $126
0 · Reply
sandman7473
sandman7473 Nov. 9 at 10:29 PM
$PLRX tutes buy after the collapse. This is either going to moon after data or a liquidation event. Just my thoughts. Gl next week.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 7:19 PM
RBC Capital has adjusted their stance on Pliant Therapeutics ( $PLRX ), setting the rating to Sector Perform with a target price of 3 → 2.
0 · Reply
KMKuk2lg2022
KMKuk2lg2022 Nov. 7 at 3:38 PM
$PLRX management and board a dogsh*t and everything is wrong with biotech! They are burning through cash and no end in sight! After the shitty data on IPF they should have done what Third Harmonic did and go for shutdown...Considering very few phase 2b or phase 3 drug candidates out there to buy or license, they can only go for reverse merger if all the folks like Tang who bought at 3.44$ want PLRX to be above 4$ in value. There shouldn't be any bonus or upping options for them. 9 months of burning cash is not on! So crazy...
1 · Reply
d_risk
d_risk Nov. 7 at 3:53 AM
$PLRX - Pliant Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors PLRX’s latest 10-Q risk factors spotlight deepening net losses, higher funding needs after discontinuing bexotegrast in IPF, unpredictable clinical and regulatory timelines, and heavy reliance on third parties. New risks include failed opportunity evaluations, exclusive forum bylaws, data protection compliance, cybersecurity, Brexit, tax law changes, analyst coverage, and social media missteps. #Biotechnology #Cybersecurity #RegulatoryUncertainty #FinancialRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/PLRX/10-Q/2025-11-06
0 · Reply
sandman7473
sandman7473 Nov. 7 at 12:32 AM
$PLRX muted as expected. Is point72 and tang waiting for data eoy? Gl.
0 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 6 at 9:07 PM
$PLRX Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results https://ir.pliantrx.com/news-releases/news-release-details/pliant-therapeutics-provides-corporate-update-and-reports-17 As of September 30, 2025, the Company had cash, cash equivalents and short-term investments of $243.3 million.
0 · Reply
Vinniesb
Vinniesb Nov. 6 at 5:22 PM
0 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 4 at 8:54 PM
$PLRX i increased my position today. News anyday
0 · Reply
ACInvestorBlog
ACInvestorBlog Nov. 4 at 7:23 PM
$PLRX another potential $EVOK before the end of the year
2 · Reply
NolAsrtormZ
NolAsrtormZ Nov. 1 at 6:46 PM
$GRI $0 or. $126 Most Failed ipf trials were worth 300 million market cap. $ARCT $PLRX $TVRD The most we can lose is 4 million market cap.
1 · Reply
ACInvestorBlog
ACInvestorBlog Oct. 31 at 7:48 PM
$PLRX I still waiting for news... patience is key
0 · Reply
sandman7473
sandman7473 Oct. 31 at 3:36 PM
$PLRX dp print yesterday at 1.76. Watch that level.
0 · Reply
sandman7473
sandman7473 Oct. 29 at 7:39 PM
$PLRX cup and handle in play. Waiting on data by eoy.
0 · Reply
NolAsrtormZ
NolAsrtormZ Oct. 27 at 7:39 PM
$GRI*NEWSFLASH* THE MOST WE CAN LOSE IS 5.1MILLION MARKET CAP. If iPf Data is good Gri bio should be rewarded from what the others lost🤑🤑🤑🤑😝😝😝🤑🤭 Give is that $TVRD 300 million market cap that they lost Give us that $ARCT 300 million market cap that they lost Give us that $PLRX 900 million market cap they lost $0 or $126
0 · Reply
NolAsrtormZ
NolAsrtormZ Oct. 27 at 7:06 PM
$GRI luv seeing Failed iPf trials stocks go down by HUNDREDS OF MILLIONS IN MARKET CAP When we cant get above 5 million market cap w pending iPf data $TVRD lost over 300 million $ARCT lost over 300 million $PLRX lost over 900 million 🤑🤑🤑🤑🤑
0 · Reply
sandman7473
sandman7473 Oct. 27 at 3:39 PM
$PLRX that dp print at 1.80 is acting as support.
0 · Reply
ACInvestorBlog
ACInvestorBlog Oct. 27 at 1:07 PM
$PLRX still in play for me. Lets see if it breaks the $2.X level this week.
0 · Reply
trading_signal
trading_signal Oct. 27 at 1:04 PM
Stocks Watchlist for today $PLRX - potential cup and handle $ASST - Momentum play $BYND - Squeeze play
1 · Reply
yo_itsmattyp
yo_itsmattyp Oct. 27 at 4:10 AM
$PLRX $260 milly in cash only 60mil in debt. Current market cap is 100M. Easily a double as support has been found between $1.60 to 1.80. Above $1.90 and a cover squeeze will start to occur and likely reach above $3S. Easy money if ur patient. $PSQH semi low float 30M, 10% short float and a rounding bottom forming last couple months creating higher lows. Looking for a gamma type pop before eoy. Last one occurred 12 months ago in December 2024 from $2 to $8. $OPEN hourly flag pattern formed and breakout occurring if price supports above $8 this week. Retest of $10 before earnings and then new resistance tested to$13 or higher depending on any market sell offs afer fed rate announcement. $BYND just gambling at this point but would definitely buy some calls when it drops below $1.50 this week. Good luck to all!!!
0 · Reply
ACInvestorBlog
ACInvestorBlog Oct. 24 at 6:54 PM
$PLRX Next Major Catalyst Before Year-End 2025 The primary upcoming catalyst is initial safety and efficacy data from the two highest dose cohorts (1600 mg and 2000 mg BID) of the ongoing Phase 1 dose-escalation trial for PLN-101095. Topline data expected by the end of 2025. Recent 13G filings from Tang Capital (a known "liquidator") and Point72 have fueled buzz a potential MA.... Trading at 50% discount to cash, seems to be a good risk/reward candidate at current levels. Do your own DD.
0 · Reply